CME Background

Articles are selected for credit designation based on an assessment of the educational needs of CME participants, with the purpose of providing readers with a curriculum of CME articles on a variety of topics throughout each volume. Activities are planned using a process that links identified needs with desired results.

CME Objective

After studying this article, you should be able to:

• Take steps to improve coordination of medical and psychiatric care for patients with severe mental illness (eg, those taking second-generation antipsychotics who need metabolic monitoring)

Statement of Need and Purpose

People with SMI have a high prevalence of somatic conditions compared to the general population. For example, patients who are taking SGAs are at risk for metabolic syndrome. Despite guidelines recommending that clinicians obtain measures of metabolic parameters in patients taking SGAs at baseline and throughout treatment, monitoring rates are low. Clinicians need education about ways to (1) comply with health monitoring guidelines for patients taking SGAs and (2) improve collaboration that addresses both the mental and physical health of patients.

Release, Expiration, and Review Dates

This educational activity was published in July 2019 and is eligible for AMA PRA Category 1 Credit™ through August 31, 2021. The latest review of this material was July 2019.

Disclosure of off-label usage

The authors have determined that, to the best of their knowledge, no investigational information about pharmaceutical agents that is outside US Food and Drug Administration-approved labeling has been presented in this article.

Funding/support

This work was supported by a Minnesota Department of Health Rural Family Medicine Residency Grant.

Role of the sponsor

The sponsor played no role in the design and conduct of the study; collection, management, analysis, and interpretation of data; or preparation, review or approval of the manuscript.

Previous presentation

A subset of the manuscript was presented by Ms O’ Donnell as a poster at the Annual Meeting of the College of Psychiatric and Neurologic Pharmacists (CPNP); April 7-10, 2019; Salt Lake City, Utah.

Acknowledgments

The authors acknowledge the Interprofessional Education and Practice Development Collaborative; John Wood, MD, University of Minnesota Duluth Family Medicine Residency Program Director; Lisa Prusak, MD, University of Minnesota Duluth Family Medicine Residency Associate Program Director; Steve Bauer, MD, Human Development Center Medical Director; and Matthew B. Hammitt, Human Development Center Health Information Manager. The acknowledged individuals report no conflicts of interest related to the subject of this article.